Pharmacological Management of Hemophilia Quiz

Factor VIII deficiency is characteristic of hemophilia A.

Hemophilia B is due to Factor IX deficiency.

The primary goal of hemophilia treatment is to maintain normal clotting factor levels.

Spontaneous joint hemorrhages are characteristic of hemophilia.

Hemophilia is primarily inherited in an X-linked recessive manner.

Decreased platelet count is not a symptom of hemophilia.

Activated partial thromboplastin time (aPTT) is typically prolonged in hemophilia.

Factor replacement therapy is the primary treatment for hemophilia.

Thrombosis is not a typical complication of hemophilia treatment.

Hemophilia B is also referred to as Christmas disease.

Long-term prophylactic treatment in hemophilia is associated with an increased risk of inhibitor development.

Cryoprecipitate is used to provide clotting factor replacement in hemophilia.

Factor inhibitor development is a complication of hemophilia treatment with clotting factor concentrates.

Activated partial thromboplastin time (aPTT) is used to assess the severity of hemophilia.

Clotting factor replacement therapy is the recommended treatment for acute joint bleeds in hemophilia.

Intracranial hemorrhage is a potential complication of hemophilia affecting the central nervous system.

Genetic counseling for hemophilia informs families about inheritance patterns and associated risks.

Bleeding into the skin or mucous membranes is a common symptom of hemophilia in infants.

Female carriers of hemophilia have a 50% chance of passing the gene to their offspring.

Hemophilia C typically presents with mucosal bleeding.

Recombinant factor VIII acts by replacing the deficient factor in hemophilia A.

Rituximab is commonly used for immune tolerance induction in hemophilia.

Emicizumab enhances factor VIII activity in the treatment of hemophilia.

Genetic mutations contribute to the development of inhibitors in hemophilia.

Desmopressin (DDAVP) acts by releasing von Willebrand factor in the treatment of hemophilia.